Cis-dichlorodiammineplatinum (II) (cis-platinum) and etoposide for patients with refractory lymphomas

Page 1

	Year	Citations
Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas G Mathé, L Schwarzenberg, P Pouillart, Cancer PathologyPharmacotherapyMetronomic ChemotherapyTumor BiologyVp 16213	1974	118
A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213 Geoffrey Falkson, J. J. Van Dyk, Errol B. van Eden, Cancer Nsc 141540PharmacologyGastroenterologyClinical PharmacologyOral Medicine	1975	97
Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia—Haematosarcoma and Solid Tumours BMJ	1973	89
Pyogenic cocci in infantile eczema throughout one year. Ruth Smith, V. G. Alder, R. P. Warin BMJ Medical MicrobiologyAntimicrobial SusceptibilityAntibioticsMedicineHealthcare-associated Infection	1975	88
Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B Nis I. Nissen, Thomas F. Pajak, Louis A. Leone, Cancer	1980	69
Evaluation of VP-16-213 in malignant lymphoma and melanoma. Cecil Jw, Quagliana Jm, Coltman Ca, PubMed Hematological MalignancyTumor BiologyLymphoid NeoplasiaMalignant DiseaseMedicine	1978	34
Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study. Rossof Ah, Coltman Ca, Jones Se, PubMed Southwest Oncology GroupImmunologyPathologyPharmacotherapyImmunotherapy	1980	20

Page 1